Potential therapeutic targets in cirrhotic cardiomyopathy

Massimo Pozzi, Laura Ratti, Cristina Guidi, Maria Milanese, Giuseppe Mancia

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cirrhotic cardiomyopathy is a recently identified pathological condition defined as "a chronic cardiac dysfunction in patients with cirrhosis characterized by blunted contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities, in the absence of known cardiac disease". Overall there seems to be a link between the progression of liver function impairment, the development of portal hypertension and the degree of hyperdynamic circulation, the hallmark of the deranged cardiovascular function in advanced liver diseases. Although mechanical factors contribute to much of the increased resistance within the liver in portal hypertension, there is clearly a vasculogenic component to the development, perpetuation and progression of this syndrome as well. The vascular component of portal hypertension includes an increase in splanchnic blood flow, as well as an increase in intrahepatic vascular resistance. Dysregulation of the nitric oxide system appears to play a key role in both these processes with a paradoxical reduction of intrahepatic availability despite increased disposal in the splanchnic and other vascular districts with adverse effects on cardiac function and structure. Nevertheless, other putative mediators of cardiac damage in cirrhosis have been proposed and their role in the pathogenesis of cirrhotic cardiomyopathy investigated. This review involves a discussionof data achieved on pathogenesis and clinical features of cirrhotic cardiomyopathy but mainly focuses on considerations on potential therapeutic targets, in the light of the evidence that this mainly subclinical condition merges to clinical relevance when challenged with those therapeutic interventions and procedures currently employed to treat the major complications of cirrhosis that might produce a negative impact on the cardiovascular system.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume7
Issue number1
Publication statusPublished - Mar 2007

Fingerprint

Portal Hypertension
Cardiomyopathies
Fibrosis
Viscera
Blood Vessels
Liver
Cardiovascular System
Vascular Resistance
Liver Diseases
Heart Diseases
Nitric Oxide
Therapeutics

Keywords

  • Cirrhotic cardiomyopathy
  • Diastolic dysfunction
  • Drug targets
  • Hyperdynamic circulation
  • Peripheral vasodilation
  • Portal hypertension

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

Pozzi, M., Ratti, L., Guidi, C., Milanese, M., & Mancia, G. (2007). Potential therapeutic targets in cirrhotic cardiomyopathy. Cardiovascular and Hematological Disorders - Drug Targets, 7(1), 21-26.

Potential therapeutic targets in cirrhotic cardiomyopathy. / Pozzi, Massimo; Ratti, Laura; Guidi, Cristina; Milanese, Maria; Mancia, Giuseppe.

In: Cardiovascular and Hematological Disorders - Drug Targets, Vol. 7, No. 1, 03.2007, p. 21-26.

Research output: Contribution to journalArticle

Pozzi, M, Ratti, L, Guidi, C, Milanese, M & Mancia, G 2007, 'Potential therapeutic targets in cirrhotic cardiomyopathy', Cardiovascular and Hematological Disorders - Drug Targets, vol. 7, no. 1, pp. 21-26.
Pozzi, Massimo ; Ratti, Laura ; Guidi, Cristina ; Milanese, Maria ; Mancia, Giuseppe. / Potential therapeutic targets in cirrhotic cardiomyopathy. In: Cardiovascular and Hematological Disorders - Drug Targets. 2007 ; Vol. 7, No. 1. pp. 21-26.
@article{ac4ce10261c04c92a7f31eacfa52d21b,
title = "Potential therapeutic targets in cirrhotic cardiomyopathy",
abstract = "Cirrhotic cardiomyopathy is a recently identified pathological condition defined as {"}a chronic cardiac dysfunction in patients with cirrhosis characterized by blunted contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities, in the absence of known cardiac disease{"}. Overall there seems to be a link between the progression of liver function impairment, the development of portal hypertension and the degree of hyperdynamic circulation, the hallmark of the deranged cardiovascular function in advanced liver diseases. Although mechanical factors contribute to much of the increased resistance within the liver in portal hypertension, there is clearly a vasculogenic component to the development, perpetuation and progression of this syndrome as well. The vascular component of portal hypertension includes an increase in splanchnic blood flow, as well as an increase in intrahepatic vascular resistance. Dysregulation of the nitric oxide system appears to play a key role in both these processes with a paradoxical reduction of intrahepatic availability despite increased disposal in the splanchnic and other vascular districts with adverse effects on cardiac function and structure. Nevertheless, other putative mediators of cardiac damage in cirrhosis have been proposed and their role in the pathogenesis of cirrhotic cardiomyopathy investigated. This review involves a discussionof data achieved on pathogenesis and clinical features of cirrhotic cardiomyopathy but mainly focuses on considerations on potential therapeutic targets, in the light of the evidence that this mainly subclinical condition merges to clinical relevance when challenged with those therapeutic interventions and procedures currently employed to treat the major complications of cirrhosis that might produce a negative impact on the cardiovascular system.",
keywords = "Cirrhotic cardiomyopathy, Diastolic dysfunction, Drug targets, Hyperdynamic circulation, Peripheral vasodilation, Portal hypertension",
author = "Massimo Pozzi and Laura Ratti and Cristina Guidi and Maria Milanese and Giuseppe Mancia",
year = "2007",
month = "3",
language = "English",
volume = "7",
pages = "21--26",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Potential therapeutic targets in cirrhotic cardiomyopathy

AU - Pozzi, Massimo

AU - Ratti, Laura

AU - Guidi, Cristina

AU - Milanese, Maria

AU - Mancia, Giuseppe

PY - 2007/3

Y1 - 2007/3

N2 - Cirrhotic cardiomyopathy is a recently identified pathological condition defined as "a chronic cardiac dysfunction in patients with cirrhosis characterized by blunted contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities, in the absence of known cardiac disease". Overall there seems to be a link between the progression of liver function impairment, the development of portal hypertension and the degree of hyperdynamic circulation, the hallmark of the deranged cardiovascular function in advanced liver diseases. Although mechanical factors contribute to much of the increased resistance within the liver in portal hypertension, there is clearly a vasculogenic component to the development, perpetuation and progression of this syndrome as well. The vascular component of portal hypertension includes an increase in splanchnic blood flow, as well as an increase in intrahepatic vascular resistance. Dysregulation of the nitric oxide system appears to play a key role in both these processes with a paradoxical reduction of intrahepatic availability despite increased disposal in the splanchnic and other vascular districts with adverse effects on cardiac function and structure. Nevertheless, other putative mediators of cardiac damage in cirrhosis have been proposed and their role in the pathogenesis of cirrhotic cardiomyopathy investigated. This review involves a discussionof data achieved on pathogenesis and clinical features of cirrhotic cardiomyopathy but mainly focuses on considerations on potential therapeutic targets, in the light of the evidence that this mainly subclinical condition merges to clinical relevance when challenged with those therapeutic interventions and procedures currently employed to treat the major complications of cirrhosis that might produce a negative impact on the cardiovascular system.

AB - Cirrhotic cardiomyopathy is a recently identified pathological condition defined as "a chronic cardiac dysfunction in patients with cirrhosis characterized by blunted contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities, in the absence of known cardiac disease". Overall there seems to be a link between the progression of liver function impairment, the development of portal hypertension and the degree of hyperdynamic circulation, the hallmark of the deranged cardiovascular function in advanced liver diseases. Although mechanical factors contribute to much of the increased resistance within the liver in portal hypertension, there is clearly a vasculogenic component to the development, perpetuation and progression of this syndrome as well. The vascular component of portal hypertension includes an increase in splanchnic blood flow, as well as an increase in intrahepatic vascular resistance. Dysregulation of the nitric oxide system appears to play a key role in both these processes with a paradoxical reduction of intrahepatic availability despite increased disposal in the splanchnic and other vascular districts with adverse effects on cardiac function and structure. Nevertheless, other putative mediators of cardiac damage in cirrhosis have been proposed and their role in the pathogenesis of cirrhotic cardiomyopathy investigated. This review involves a discussionof data achieved on pathogenesis and clinical features of cirrhotic cardiomyopathy but mainly focuses on considerations on potential therapeutic targets, in the light of the evidence that this mainly subclinical condition merges to clinical relevance when challenged with those therapeutic interventions and procedures currently employed to treat the major complications of cirrhosis that might produce a negative impact on the cardiovascular system.

KW - Cirrhotic cardiomyopathy

KW - Diastolic dysfunction

KW - Drug targets

KW - Hyperdynamic circulation

KW - Peripheral vasodilation

KW - Portal hypertension

UR - http://www.scopus.com/inward/record.url?scp=33947150894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947150894&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 21

EP - 26

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 1

ER -